-- Data Presented at American Society of Hematology (ASH) Annual Meeting -- With a median follow-up of 12.3 months (range: 7.0 to 32.3 months) at the time of data cutoff, 57 percent of patients ...
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ ...
The company announced yesterday's planned launch of the Falcon 9 rocket, Zuma spacecraft and its mysterious payload will not take off until January 7. This is the latest in a long series of delays ...
ORLANDO, Fla.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-2, a global, multicenter, single-arm, open-label Phase 2 study of KTE-X19, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback